CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Washington, District of Columbia, United States and 212 other locations
and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer....
Phase 1, Phase 2
Baltimore, Maryland, United States
or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcino...
Phase 1
Baltimore, Maryland, United States
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitr...
Phase 1
Baltimore, Maryland, United States and 32 other locations
to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...
Phase 1, Phase 2
Washington, District of Columbia, United States and 83 other locations
the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon...
Phase 2, Phase 3
Washington, District of Columbia, United States and 827 other locations
This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.
Phase 1
Fairfax, Virginia, United States and 6 other locations
safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer...
Phase 2
Baltimore, Maryland, United States
A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of ²¹²Pb-DOTAM-GRPR1 in subjects with various GRPR-ex...
Phase 1
Glen Burnie, Maryland, United States and 3 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Phase 1
Fairfax, Virginia, United States and 14 other locations
Clinical trials
Research sites
Resources
Legal